One preclinical study demonstrated that LSD1/KDM1A inhibition with a small molecule (ORY-1001) induced H3K4me2 accumulation on KDM1A target genes, resulting in blast differentiation and reduced leukemia burden in cell line and animal models of MLL-rearranged T-acute lymphoblastic leukemia [91]. The gene discussed is KMT2A; the disease is leukemia.